Prognostic Utility of Tumor-Infiltrating Lymphocyte (TIL) Biomarkers Versus Anatomic TNM Staging in Resected Pancreatic Ductal Adenocarcinoma: A Scoping Review

views comments

Ethan Dull, OMS-II; Elquis Castillo II, OMS-II; Brandon M. Plimley, OMS-II; Sergio Morizot-Leite, OMS-II; Anthony Mongelluzzo, OMS-II; Richard Melvin, OMS-II; Troy Hansen, OMS-II